

# Guanghai Dai

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5907862/publications.pdf>

Version: 2024-02-01

22  
papers

98  
citations

1478505

6  
h-index

1474206

9  
g-index

23  
all docs

23  
docs citations

23  
times ranked

148  
citing authors

#	ARTICLE	IF	CITATIONS
1	Retinoic Acid-Induced 2 (RAI2) Is a Novel Antagonist of Wnt/ $\beta$ 2-Catenin Signaling Pathway and Potential Biomarker of Chemosensitivity in Colorectal Cancer. <i>Frontiers in Oncology</i> , 2022, 12, 805290.	2.8	4
2	A phase II single-center single-arm study of PD-1 inhibitor in combination with albumin paclitaxel and apatinib as second-line treatment of metastatic gastric cancer (mGC).. <i>Journal of Clinical Oncology</i> , 2022, 40, e16024-e16024.	1.6	0
3	Neutrophil to lymphocyte ratio (NLR), platelet to lymphocyte ratio (PLR) and hemoglobin (Hb) predict immunotherapy outcomes in patients with advanced or metastatic gastric cancer.. <i>Journal of Clinical Oncology</i> , 2021, 39, e16075-e16075.	1.6	0
4	&lt;p&gt;Programmed Cell Death Protein-1 (PD-1)-Targeted Immunotherapy for Advanced Hepatocellular Carcinoma in Real World&lt;/p&gt;. <i>OncoTargets and Therapy</i> , 2020, Volume 13, 143-149.	2.0	15
5	LncRNA HEIH promotes cell proliferation, migration and invasion in cholangiocarcinoma by modulating miR-98-5p/HECTD4. <i>Biomedicine and Pharmacotherapy</i> , 2020, 125, 109916.	5.6	24
6	A Chinese Retrospective Multicenter Study of First-Line Chemotherapy for Advanced Pancreatic Cancer. <i>Medical Science Monitor</i> , 2020, 26, e927654.	1.1	1
7	A Chinese Retrospective Multicenter Study of First-Line Chemotherapy for Advanced Pancreatic Cancer. <i>Medical Science Monitor</i> , 2020, 26, e927654.	1.1	7
8	S-1 plus oxaliplatin versus S-1 plus cisplatin as first-line treatment for advanced diffuse-type or mixed-type gastric/gastroesophageal junction adenocarcinoma: A randomized, phase 3 trial.. <i>Journal of Clinical Oncology</i> , 2019, 37, 4017-4017.	1.6	14
9	Tumor mutational burden identifies chemorefractory gastric cancer with overall survival advantage after receiving toripalimab, a PD-1 antibody.. <i>Journal of Clinical Oncology</i> , 2019, 37, 4021-4021.	1.6	3
10	Association of frequent amplification of chromosome 11q13 in esophageal squamous cell cancer with clinical benefit to immune check point blockade.. <i>Journal of Clinical Oncology</i> , 2019, 37, 4036-4036.	1.6	12
11	Recombinant humanized anti-PD-1 monoclonal antibody (JS001) in patients with refractory/metastatic nasopharyngeal carcinoma: Interim results of an open-label phase II clinical study.. <i>Journal of Clinical Oncology</i> , 2019, 37, 6017-6017.	1.6	4
12	Efficacy and safety of nivolumab in first-line or further treatment of advanced metastatic biliary tract cancer.. <i>Journal of Clinical Oncology</i> , 2019, 37, 315-315.	1.6	0
13	Apatinib combined with Raltitrexed in patients with metastatic colorectal cancer after failure of standard therapy (AHEAD-311): A single-arm phase II pilot trial.. <i>Journal of Clinical Oncology</i> , 2019, 37, e15008-e15008.	1.6	0
14	Recombinant humanized anti-PD-1 monoclonal antibody (JS001) as salvage treatment for advanced gastric adenocarcinoma: Preliminary results of an open-label, multi-cohort, phase Ib/II clinical study.. <i>Journal of Clinical Oncology</i> , 2018, 36, 108-108.	1.6	3
15	Recombinant humanized anti-PD-1 monoclonal antibody (JS001) as salvage treatment for advanced esophageal squamous cell carcinoma: Preliminary results of an open-label, multi-cohort, phase Ib/II clinical study.. <i>Journal of Clinical Oncology</i> , 2018, 36, 116-116.	1.6	9
16	A prospective multicenter observational study of bevacizumab for the treatment of metastatic colorectal cancer in Chinese patients (Obtain study).. <i>Journal of Clinical Oncology</i> , 2018, 36, e15560-e15560.	1.6	0
17	Night shift work duration and risk of colorectal cancer according to IRS1 and IRS2 expression.. <i>Journal of Clinical Oncology</i> , 2018, 36, 3571-3571.	1.6	0
18	The efficiency of apatinib plus S-1 as second-line or laterline chemotherapy for advanced non-small-cell lung cancer.. <i>Journal of Clinical Oncology</i> , 2017, 35, e20549-e20549.	1.6	0

#	ARTICLE	IF	CITATIONS
19	A phase II study of Chinese patients (pts) treated with nab-paclitaxel (nab-P) plus gemcitabine (Gem) for metastatic pancreatic cancer (MPC).. Journal of Clinical Oncology, 2016, 34, 327-327.	1.6	2
20	Final analysis of the phase 2 APEC study: Overall survival (OS) data and biomarker subanalyses for first-line FOLFOX or FOLFIRI with cetuximab (cet) once every 2 weeks in patients (pts) with KRAS or RAS (KRAS and NRAS, exons 2-4) wild-type (wt) metastatic colorectal cancer (mCRC).. Journal of Clinical Oncology, 2015, 33, 566-566.	1.6	0
21	Efficacy and safety of every-2-weeks cetuximab combined with FOLFOX or FOLFIRI as first-line therapy in patients with KRAS wild-type metastatic colorectal cancer (mCRC): An Asia-Pacific nonrandomized phase II study (APEC).. Journal of Clinical Oncology, 2013, 31, e14501-e14501.	1.6	0
22	Randomized double-blind clinical comparison of sodium ibandronate and pamidronate disodium for treatment of 141 patients with malignant tumor ostealgia. Chinese Journal of Clinical Oncology, 2007, 4, 103-108.	0.0	0